Overcoming acquired resistance to EGFR inhibitors in lung cancer

克服肺癌对 EGFR 抑制剂的获得性耐药

• 批准号: 8634034
• 负责人: Christine M. Lovly
• 金额: $ 29.37万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2017-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8634034
• 关键词: Aftercare; Antibodies; Biochemical; Cancer Biology; Cell Line; Cetuximab; Clinical Trials; Development; Disease; Disease Progression; Drug Combinations; Drug-sensitive; Epidermal Growth Factor Receptor; Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor; Erlotinib; Exons; Funding; Gefitinib; Gene Amplification; Generations; Genetic Engineering; Goals; Grant; Human; Knowledge; Ligands; Lung Neoplasms; Malignant neoplasm of lung; Mediating; Modeling; Molecular; Molecular Analysis; Mutation; Patients; Phase; Phosphotransferases; Play; Pre-Clinical Model; Progressive Disease; Protein Tyrosine Kinase; Receptor Inhibition; Receptor Protein-Tyrosine Kinases; Receptor Signaling; Recurrence; Resistance; Resistance development; Role; Signal Pathway; Site; Specimen; Techniques; Testing; Tissues; Transgenic Mice; Tumor Tissue; Tyrosine Kinase Domain; Work; Xenograft procedure; base; cancer cell; cohort; design; experience; improved; insight; mouse model; mutant; neoplastic cell; novel; pre-clinical; receptor internalization; resistance mechanism; response; therapeutic target; tumor

DESCRIPTION (provided by applicant): Over 70% of patients whose lung cancers harbor specific mutations within the exons encoding the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) experience radiographic responses to the selective EGFR tyrosine kinase inhibitors (TKIs), gefitinib (Iressa) or erlotinib (Tarceva). However, after about one year, these patients develop progression of disease. No targeted therapy has proven clinically effective in treating acquired resistance. In the previously funded period, we identified several mechanisms of acquired resistance, including second-site EGFR mutations (>50% of cases) and amplification of the gene encoding the MET tyrosine kinase (up to 20% of cases). Using mouse models of lung cancer that we generated and characterized, we also showed that the most common form of resistance, mediated by the EGFR T790M mutation, could be overcome by a novel combination of the second-generation EGFR TKI, afatinib (BIBW2992), and the anti-EGFR antibody, cetuximab. A Phase IB/II clinical trial of this combination in humans has now shown unprecedented activity in this patient cohort with a 36% (8 of 22) radiographic response rate. However, at least one patient on this combination has already developed progressive disease, and surprisingly, some tumors without T790M have also responded. The overall goals of this revised proposal are to use human tumor specimens and cell lines, genetically engineered and xenograft mouse models, and various molecular and biochemical techniques to gain further knowledge about the subset of EGFR mutant harboring lung cancers that develop acquired resistance to EGFR inhibition. An improved understanding of acquired resistance will hopefully allow us to treat/suppress the development of progressive disease and provide new insights into the biology of cancers driven by EGFR or other mutant receptor tyrosine kinases.

描述（由申请方提供）：超过70%的肺癌患者在编码表皮生长因子受体（EGFR）酪氨酸激酶结构域的外显子内携带特异性突变，对选择性EGFR酪氨酸激酶抑制剂（TKI）、吉非替尼（易瑞沙）或厄洛替尼（特罗凯）有放射学反应。然而，大约一年后，这些患者出现疾病进展。没有靶向治疗已被证明在治疗获得性耐药性的临床有效性。在之前的资助期间，我们确定了几种获得性耐药的机制，包括第二位点EGFR突变（>50%的病例）和编码MET酪氨酸激酶的基因扩增（高达20%的病例）。使用我们生成和表征的肺癌小鼠模型，我们还表明，由EGFR T790 M突变介导的最常见的耐药形式可以通过第二代EGFR TKI阿法替尼（BIBW 2992）和抗EGFR抗体西妥昔单抗的新型组合来克服。该组合在人体中的IB/II期临床试验现已在该患者队列中显示出前所未有的活性，放射学缓解率为36%（8/22）。然而，至少有一名接受这种组合的患者已经出现了进展性疾病，令人惊讶的是，一些没有T790 M的肿瘤也有反应。本修订提案的总体目标是使用人类肿瘤标本和细胞系、基因工程和异种移植小鼠模型以及各种分子和生物化学技术，以获得关于EGFR突变型肺癌亚组的进一步知识，这些肺癌对EGFR抑制产生获得性耐药性。对获得性耐药的进一步了解将有望使我们能够治疗/抑制进展性疾病的发展，并为EGFR或其他突变型受体酪氨酸激酶驱动的癌症生物学提供新的见解。